
DRTS Stock Forecast & Price Target
DRTS Analyst Ratings
Bulls say
Alpha Tau Medical is a clinical-stage oncology therapeutics company with a proprietary technology utilizing alpha particles for targeted radiation therapy in a variety of solid tumor types. The company's active clinical programs and geographical diversification offer potential for long-term growth, while recent data from U.S. regulatory trials and promising interim results in recurrent glioblastoma reinforce the potential efficacy of their treatment. Additionally, the company's cash runway through 2027 provides a solid financial foundation for continued development and potential expansion into new indications.
Bears say
Alpha Tau Medical is a clinical-stage oncology therapeutics company with a focused proprietary technology designed to overcome the traditional limitations of alpha radiation. While the company has active clinical programs targeting various tumor types and has received FDA approval for expansion of its pancreatic cancer pilot trial, the company's topline data for its pivotal ReSTART trial is not expected until the end of 2026. The company's valuation is estimated to be $1.30B, with a 12-month price target of $15 per share and potential risks include the failure of Alpha DaRT to secure regulatory approval and achieve commercial success.
This aggregate rating is based on analysts' research of Alpha Tau Medical and is not a guaranteed prediction by Public.com or investment advice.
DRTS Analyst Forecast & Price Prediction
Start investing in DRTS
Order type
Buy in
Order amount
Est. shares
0 shares